Pier 88 Investment Partners LLC Sells 7,150 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Pier 88 Investment Partners LLC lessened its position in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 41.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,240 shares of the biopharmaceutical company’s stock after selling 7,150 shares during the period. Pier 88 Investment Partners LLC’s holdings in Horizon Therapeutics Public were worth $816,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Valley National Advisers Inc. increased its holdings in Horizon Therapeutics Public by 21.2% during the 1st quarter. Valley National Advisers Inc. now owns 801 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 140 shares in the last quarter. Lebenthal Global Advisors LLC grew its holdings in shares of Horizon Therapeutics Public by 5.8% in the 2nd quarter. Lebenthal Global Advisors LLC now owns 2,669 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 147 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Horizon Therapeutics Public by 0.3% in the 2nd quarter. Arizona State Retirement System now owns 60,139 shares of the biopharmaceutical company’s stock valued at $4,797,000 after acquiring an additional 158 shares in the last quarter. Aspire Private Capital LLC grew its holdings in shares of Horizon Therapeutics Public by 2.3% in the 2nd quarter. Aspire Private Capital LLC now owns 7,082 shares of the biopharmaceutical company’s stock valued at $565,000 after acquiring an additional 158 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Horizon Therapeutics Public by 0.4% in the 1st quarter. US Bancorp DE now owns 44,359 shares of the biopharmaceutical company’s stock valued at $4,667,000 after acquiring an additional 179 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Horizon Therapeutics Public Stock Performance

HZNP stock traded up $0.26 during mid-day trading on Thursday, hitting $77.53. 1,297,155 shares of the company were exchanged, compared to its average volume of 2,766,304. The business has a 50 day simple moving average of $67.51 and a 200-day simple moving average of $74.32. The company has a current ratio of 3.96, a quick ratio of 3.74 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $17.57 billion, a PE ratio of 31.77, a price-to-earnings-growth ratio of 1.54 and a beta of 1.09. Horizon Therapeutics Public Limited has a 1-year low of $57.84 and a 1-year high of $117.49.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HZNP shares. BMO Capital Markets decreased their price objective on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a report on Thursday, August 4th. UBS Group cut Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $137.00 to $71.00 in a report on Thursday, August 4th. SVB Leerink raised their price objective on Horizon Therapeutics Public from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Thursday, November 3rd. Morgan Stanley decreased their price objective on Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating for the company in a report on Thursday, August 4th. Finally, HC Wainwright initiated coverage on Horizon Therapeutics Public in a report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.